Trevi Therapeutics (TRVI) Tops Q3 EPS by 2c

Trevi Therapeutics (NASDAQ: TRVI) reported Q3 EPS of ($0.08), $0.02 better than the analyst estimate of ($0.10).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Pfizer executive says China now leads Europe in drug innovation
• SpaceX bond sale draws $89 billion in investor demand